Responsible Marketing

Evidence-based Marketing

Annual Congress of the European Society of Cardiology held in Madrid, Spain (ESC Congress 2025)
Hanmi Pharmaceutical presented its findings at the globally renowned cardiovascular conference, ESC Congress 2025, where it presented the results of its Phase 3 clinical study for Amoprel, the world's first ultra-low-dose triple-combination antihypertensive drug, and the results of its Phase 4 clinical study for Amosartan XQ, a quadruple-combination drug for the concomitant treatment of hypertension and dyslipidemia. Held in Madrid, Spain, from August 29 to September 1, 2025, this conference is the largest academic event in the cardiovascular field, with over 30,000 experts participating from more than 150 countries worldwide. Two Phase 3 clinical studies of Amoprel compared the blood pressure-lowering effect over 8 weeks against standard monotherapies (Amlodipine 5mg, Losartan 50mg) in Korean patients with essential hypertension. The study results confirmed equivalence or superiority in terms of reductions in systolic and diastolic blood pressure, and the target blood pressure achievement rate was also significantly higher. No serious adverse drug reactions were reported, confirming excellent tolerability. This clinical excellence was published in JACC, the official journal of the American College of Cardiology, in February 2026, marking the first time a Phase 3 clinical trial for an antihypertensive drug developed by a domestic company has been published, drawing increasing attention recently as a new paradigm for initial hypertension therapy. The AMOREMIO clinical study of Amosartan XQ evaluated the therapeutic efficacy and compliance of Amosartan XQ tablets in patients with atherosclerotic cardiovascular disease who had low adherence. The study results showed a significant simultaneous improvement in blood pressure and lipid levels, along with increased treatment satisfaction. Specifically, the likelihood of achieving LDL-C below 70mg/dL was 3.7 times higher compared to existing treatments, and the likelihood of achieving systolic blood pressure below 140mmHg was 3.08 times higher, confirming the clinical value of the combination drug in terms of therapeutic efficacy and medication convenience. In addition to this evidence-based marketing, Amosartan XQ expanded its lineup to a total of 8 doses by launching two additional low-dose strengths (5/50/2.5/10mg, 5/100/2.5/10mg) in December 2025, thereby enhancing dose selectivity. These research results are expected to provide important evidence for a paradigm shift in initial hypertension therapy and the clinical value of combination-based treatment strategies in patients with concomitant dyslipidemia.

Product-specific Evidence-based Sales and Marketing Key Activities

Digital Marketing

HMP: Professional Portal for Healthcare Professionals

Celebrating its 25th anniversary in 2025, HMP continues to strengthen trust-based communication with healthcare professionals through its digital platform. Through a 25th-anniversary customer appreciation event, we reflected on our long-standing relationships with healthcare professionals and expanded the scope of customer participation and communication by operating participatory programs such as a new drug naming contest. Furthermore, daily LIVE symposia provide medical information covering various diseases and treatment topics, and the 1:1 video detailing service i-Hanmi enhances healthcare professionals' information accessibility and convenience.

In addition, as a result of various digital-based communication activities, including performing a role as a platform hub for social contribution in conjunction with the Lim Sung Ki Foundation, Big Heart Plus, and others, Hanmi Pharmaceutical has ranked first for 6 consecutive years in a survey conducted by the doctor portal Medigate, continuously confirming the trustworthiness of its platform.

July 2025: HMP 25th Anniversary Customer Appreciation Event	Dec. 2025 Medical Professional Portal 'HMP'

Video detailing service 'i-Hanmi'

Hanmi Pharmaceutical provides an 'i-Hanmi' 1:1 video detailing service, allowing customers to receive key product/disease information in just "5 minutes" at their preferred time and location. Through interactive 1:1 detailing, we deliver not only product and disease information but also the latest evidence-based medical information, including domestic and international guidelines, reimbursement criteria, and overseas prescribing trends, all of which are helpful for patient care.

Disease Video Campaign 'Doctor in My Ear'

The disease video campaign 'My Ear Doctor' is a public campaign that helps people manage, prevent, and treat diseases by sharing the expertise of renowned doctors and information on major diseases that are of high public interest. The proceeds from the YouTube channel are entirely donated to patients, contributing to social contribution activities, and a cumulative 10 million KRW in proceeds have been donated to pediatric patients, sharing warm hearts with participating medical staff. Hanmi Pharmaceutical continuously practices responsible digital marketing that contributes to the medical ecosystem.

2025.05.30 'My Ear Doctor' Cumulative Profit 10 Million KRW Donation Ceremony to Patients

Hanmi Pharmaceutical Ranks #1 in Digital Marketing Excellence for 6 Consecutive Years
Hanmi Pharmaceutical was ranked #1 for 6 consecutive years, with 51.1% among general hospitals and 50.4% among clinics, as the domestic pharmaceutical company whose digital marketing activities were rated as 'excellent' by customers.

* Source: Pharmaceutical companies with good digital marketing chosen by doctors...GSK and Chong Kun Dang's brand awareness increased compared to the previous year (Medigate News / 2025.08.28.)

Ethical Marketing

Hanmi Pharmaceutical complies with relevant laws and regulations and the Ministry of Food and Drug Safety guidelines in its pharmaceutical advertising and promotional activities, carrying out marketing activities based on ethical standards. Particularly, it prioritizes the accurate and reliable dissemination of information that can contribute to patient treatment by providing healthcare professionals with not only the latest medical information but also balanced information on efficacy and safety. Furthermore, to establish fair competitive order, it strictly prohibits false/exaggerated advertising and improper marketing activities, continuously strengthening an ethical marketing environment through relevant internal standards and review procedures.

Management of Pharmaceutical Promotional Materials

All marketing-related materials at Hanmi Pharmaceutical are systematically managed according to relevant laws and internal compliance standards and are operated through a pre-review process based on the 'Pharmaceutical Promotional Material Review Regulations'. These materials are prepared based on approved product information and scientific evidence, and are approved after verifying medical validity and information accuracy through Medical (MIS (medical information specialist), Medical Director) review.

Pharmaceutical Promotional Material Management Process

Accurate Product Information and labeling materials Management

Considering the characteristics of specialized pharmaceuticals, Hanmi Pharmaceutical strictly limits promotional and marketing activities targeting the general public in accordance with relevant laws. All product information is accurately prepared based on approved product information and scientific evidence, and relevant laws and internal standards are observed throughout the information dissemination process. Furthermore, the company avoids exaggerated or misleading expressions and adheres to the principle of providing objective and reliable information. In academic activities and communications targeting healthcare professionals, efficacy and safety information of products is delivered in a balanced manner, and the appropriateness of the information recipient and scope is pre-reviewed to ensure regulatory compliance and proper information delivery.

① Products Subject to Enhanced Safety Management
Hanmi Pharmaceutical systematically manages labeling materials for accurate product information dissemination, providing essential information such as main ingredients, indications, dosage/administration, and precautions for use clearly according to relevant standards. For specialized pharmaceuticals, information based on approved product information is primarily conveyed to healthcare professionals, and when enhanced safety management (RMP, Risk Management Plan, etc.) is applied depending on product characteristics, relevant information is provided in an appropriate manner. Furthermore, labeling materials are managed to include essential information such as indications, dosage/administration, and precautions for use, thereby supporting the accuracy of product information and safe use.

② Labeling Materials and DisplayㆍAdvertising Compliance Management
Hanmi Pharmaceutical pre-reviews all product labeling materials and promotional materials for compliance with relevant laws and internal standards, operating a management system to provide accurate information based on approved product information and minimize the possibility of exaggeration or misinterpretation. Through this, the company continuously monitors the level of compliance with labeling and advertising regulations and strengthens proactive compliance management activities.

Status of Labeling and Advertising Compliance Management